GNLX Strangle Strategy
GNLX (Genelux Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX (Genelux Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $121.1M, a beta of 0.59 versus the broader market, a 52-week range of 2.29-8.535, average daily share volume of 199K, a public-listing history dating back to 2023, approximately 26 full-time employees. These structural characteristics shape how GNLX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.59 indicates GNLX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on GNLX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
GNLX snapshot
As of August 14, 2026, spot at $2.73, ATM IV 124.30%, IV rank 32.76%, expected move 35.64%. The strangle on GNLX below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on GNLX specifically: GNLX IV at 124.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 35.64% (roughly $0.97 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GNLX expiries trade a higher absolute premium for lower per-day decay. Position sizing on GNLX should anchor to the underlying notional of $2.73 per share and to the trader's directional view on GNLX stock.
GNLX strangle setup
The GNLX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GNLX at $2.73 on that close, the first option leg uses a $2.87 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GNLX chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GNLX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.87 | N/A |
| Buy 1 | Put | $2.59 | N/A |
GNLX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
GNLX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on GNLX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on GNLX
Strangles on GNLX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GNLX chain.
GNLX thesis for this strangle
The market-implied 1-standard-deviation range for GNLX extends from approximately $1.76 on the downside to $3.70 on the upside. A GNLX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current GNLX IV rank near 32.76% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on GNLX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, GNLX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GNLX-specific events.
GNLX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GNLX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GNLX alongside the broader basket even when GNLX-specific fundamentals are unchanged. Always rebuild the position from current GNLX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on GNLX?
- A strangle on GNLX is the strangle strategy applied to GNLX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With GNLX stock at $2.73 on the most recent close, the strikes shown on this page are snapped to the nearest listed GNLX chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are GNLX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the GNLX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 124.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GNLX strangle?
- The breakeven for the GNLX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The GNLX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 35.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on GNLX?
- Strangles on GNLX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GNLX chain.
- How does current GNLX implied volatility affect this strangle?
- GNLX ATM IV is at 124.30% with IV rank near 32.76%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.